VIVUS, Inc. (VVUS)
(Delayed Data from NSDQ)
$3.73 USD
+0.03 (0.81%)
Updated May 3, 2019 04:13 PM ET
After-Market: $3.83 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$3.73 USD
+0.03 (0.81%)
Updated May 3, 2019 04:13 PM ET
After-Market: $3.83 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Novartis Presents Data on Tafinlar-Mekinist Combination
by Zacks Equity Research
Novartis AG (NVS) announced results from a phase II study, BRF113220, on the combination of Tafinlar and Mekinist at the 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO).
Amgen (AMGN) Presents Positive Clinical Data on Cancer Drugs
by Zacks Equity Research
Amgen, Inc. (AMGN) presented encouraging results from a phase III study, evaluating its marketed drug Xgeva (denosumab) for an expanded indication at the American Society of Clinical Oncology.
Radius (RDUS) Announces Positive Data on Breast Cancer Drug
by Zacks Equity Research
Radius Health, Inc. (RDUS) announced encouraging results from an ongoing phase I study on pipeline candidate elacestrant (RAD1901) in patients suffering from estrogen receptor positive (ER+) breast cancer.
5 Breakout Stocks Offering Stupendous Returns
by Swarup Gupta
Such stocks offer the prospect of above-average returns.
Biogen/Ionis Spinraza Granted Marketing Authorization in EU
by Zacks Equity Research
Biogen Inc. (BIIB) announced granting of marketing authorization to its marketed drug Spinraza (nusinersen) by European Commission under the accelerated assessment program for treating patients with 5q spinal muscular atrophy.
Celgene & Acceleron Complete Enrollment on Thalassemia Drug
by Zacks Equity Research
Celgene Corporation (CELG) and Acceleron Pharma Inc. (XLRN) announced that the companies have completed target enrollment in the phase III studies, MEDALIST and BELIEVE on pipeline candidate luspatercept.
Pfizer's Kidney Cancer Drug Gets Acceptance in the U.S. & EU
by Zacks Equity Research
Pfizer Inc. (PFE) announced encouraging news with the FDA and the European Medicines Agency (EMA) accepting the company's regulatory submission for label expansion of its cancer drug, Sutent (sunitinib).
BioMarin's (BMRN) Brineura Approved by European Commission
by Zacks Equity Research
BioMarin Pharmaceutical Inc. (BMRN) announced that the European Commission has approved Brineura (cerliponase alfa) for the treatment of neuronal ceroid lipofuscinosis type 2 (CLN2).
Aduro's Drug Gets Clearance by the FDA for Solid Tumors
by Zacks Equity Research
Aduro Biotech, Inc. (ADRO) announced that the FDA has cleared the Investigational New Drug application (IND) for its pipeline candidate ADU-S100 (MIW815).
Alder BioPharmaceuticals (ALDR) Looks Good: Stock Adds 10.7% in Session
by Zacks Equity Research
Alder BioPharmaceuticals' (ALDR) nearly 11% price rise in the last session increases the inquisitiveness for the stock. Read on to know more.
Teva's Migraine Candidate TEV-48125 Positive in Phase III
by Zacks Equity Research
Teva Pharmaceutical Industries Limited (TEVA) announced positive top-line results from a phase III study (HALO), evaluating its pipeline candidate, fremanezumab (TEV-48125) for prevention of chronic migraine (CM).
Alnylam's Givosiran Gets Breakthrough Therapy Status by FDA
by Zacks Equity Research
Alnylam Pharmaceuticals, Inc. (ALNY) announced that it has received Breakthrough Therapy designation from the FDA for pipeline candidate givosiran (ALN-AS1), for the prophylaxis of attacks in patients with acute hepatic porphyria (AHP).
Eli Lilly's (LLY) Cancer Drug Cyramza Positive in Phase III
by Zacks Equity Research
Eli Lilly and Company (LLY) announced positive results from a phase III study evaluating Cyramza for expanded use in combination with docetaxel in patients with locally advanced or unresectable or metastatic urothelial carcinoma.
Novo Nordisk's (NVO) Drug Gets FDA Approval for Hemophilia B
by Zacks Equity Research
Novo Nordisk (NVO) announced that the FDA has approved the Biologics License Application (BLA) for Rebinyn (Coagulation Factor IX (Recombinant), GlycoPEGylated) for the treatment of adults and children with hemophilia B.
Gilead Single Tablet Regiment for HIV Good in Phase III
by Zacks Equity Research
Gilead Sciences, Inc. (GILD) reported positive results on four phase III studies evaluating bictegravir in combination with FTC/TAF as a single tablet regimen for HIV infection.
Ligand (LGND) Signs Licensing Deal with xCella Biosciences
by Zacks Equity Research
Ligand Pharmaceuticals Incorporated (LGND) announces it has entered into a worldwide license agreement with drug discovery company xCella Biosciences, Inc.
Pfizer's Trumenba Vaccine Approved by European Commission
by Zacks Equity Research
Pfizer Inc. (PFE) announced that its Trumenba vaccine received approval from the European Commission (EC) for active immunization of people aged 10 years and older for the prevention of invasive disease caused by Neisseria meningitidis serogroup B (MenB).
Merck's HIV Drug Isentress Gets FDA Approval for Higher Dose
by Zacks Equity Research
Merck & Co., Inc. (MRK) recently announced that the FDA has approved Isentress HD, a new 1,200 mg once daily dose of its marketed drug Isentress (raltegravir), in combination with other anti-retroviral therapies.
Bristol-Myers Partners Array to Investigate Cancer Candidate
by Zacks Equity Research
Bristol-Myers Squibb Company (BMY) and Array BioPharma (ARRY) entered into a clinical research collaboration to investigate the safety, tolerability and efficacy of Array's binimetinib in combination with the former's Opdivo and Opdivo + Yervoy regimen.
Perrigo's (PRGO) Q1 Earnings Beat Estimates, Guidance Intact
by Zacks Equity Research
Perrigo Company plc (PRGO) reported first-quarter 2017 earnings of $1.05 per share which beat the Zacks Consensus Estimate of 98 cents per share by 7.1%.
Falling Earnings Estimates Signal Weakness Ahead for Horizon Pharma (HZNP)
by Zacks Equity Research
One stock that you may want to consider dropping is Horizon Pharma Public Limited Company (HZNP), which has witnessed a significant price decline in the past four weeks
Genomic Health (GHDX) Looks Good: Stock Adds 5.2% in Session
by Zacks Equity Research
Genomic Health (GHDX) was a big mover last session, as the company saw its shares rise over 5% on the day amid huge volumes.
4 Reasons Why You Should Add Bayer Stock to Your Portfolio
by Zacks Equity Research
Bayer carries a Zacks Rank #2 (Buy) and a favorable VGM score of A.
Will Regeneron's (REGN) Newly Approved Drugs Drive Growth?
by Zacks Equity Research
We believe approval of new drugs at Regeneron will lessen the company's dependence on Eylea.
MannKind Corporation (MNKD) Catches Eye: Stock Jumps 7%
by Zacks Equity Research
MannKind Corporation (MNKD) was a big mover last session, as the company saw its shares rise over 7% on the day amid huge volumes.